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Abstract
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have
primarily been characterized according to their binding profiles. However, their ability to activate individual somatostatin
receptor subtypes (sst) has not been directly assessed so far. Here, we transplanted the carboxyl-terminal phosphorylation
motif of the sst2 receptor to other somatostatin receptors and assessed receptor activation using a set of three phosphosite-
specific antibodies. Our comparative analysis revealed unexpected efficacy profiles for pasireotide, octreotide and
somatoprim. Pasireotide was able to activate sst3 and sst5 receptors but was only a partial agonist at the sst2 receptor.
Octreotide exhibited potent agonistic properties at the sst2 receptor but produced very little sst5 receptor activation. Like
octreotide, somatoprim was a full agonist at the sst2 receptor. Unlike octreotide, somatoprim was also a potent agonist at
the sst5 receptor. Together, we propose the application of a phosphorylation probe for direct assessment of G protein-
coupled receptor activation and demonstrate its utility in the pharmacological characterization of novel somatostatin
analogs.
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Introduction
The development of novel multireceptor somatostatin analogs
has primarily focused on the discovery of compounds with
nanomolar binding affinities to more than one of the five
somatostatin receptors (sst1–sst5). It is not clear, however, whether
these compounds exhibit full or partial agonistic properties at
individual somatostatin receptor subtypes. This lack of knowledge
is due to the limited availability of methods allowing a direct
assessment of G protein-coupled receptor (GPCR) activation.
In clinical practice, octreotide and lanreotide are used as first
choice medical treatment of neuroendocrine tumors such as GH-
secreting adenomas and carcinoids [1,2]. Octreotide and lanreo-
tide bind with high sub-nanomolar affinity to sst2 only, have
moderate affinity to sst3 and sst5 and show very low or absent
binding to sst1 and sst4. Recently, the novel multireceptor
somatostatin analog, pasireotide (SOM230), has been synthesized
[3]. Pasireotide is a cyclohexapeptide, which binds with high
affinity to all somatostatin receptors except to sst4 [4]. In contrast
to octreotide, pasireotide exhibits particular high sub-nanomolar
affinity to sst5 [5]. Pasireotide is currently under clinical evaluation
for treatment of acromegaly, Cushing’s disease and octreotide-
resistant carcinoid tumors [6,7,8]. In addition to pasireotide, the
novel pan-somatostatin analog somatoprim (DG3173) is currently
under clinical and preclinical evaluation. Somatoprim exhibits
a unique binding profile in that binds with high affinity to sst2, sst4
and sst5 but not to sst1 or sst3.
We have recently uncovered agonist-selective and species-
specific patterns of sst2A receptor phosphorylation and trafficking
[9]. Whereas octreotide, in a manner similar to that observed with
somatostatin, stimulates the phosphorylation of a number of
carboxyl-terminal phosphate acceptor sites in both rat and human
sst2 receptors, pasireotide fails to promote any detectable
phosphorylation or internalization of the rat sst2A receptor. In
contrast, pasireotide is able to trigger a partial internalization of
the human sst2 receptor. At present it is unclear whether the
agonist-selective regulation of the sst2 receptor observed for
pasireotide is a general property of all pan-somatostatin analogs,
and whether such functional selectivity may exist for other
clinically-relevant somatostatin receptors including sst5 and sst3.
In the present study, we addressed this problem by using the
carboxyl-terminal tail of the sst2 receptor as transplantable
phosphorylation probe to directly sense the activation of other
somatostatin receptors. This approach was possible due to our
recent success in generating a set of three phosphosite-specific
antibodies for the sst2 receptor which allowed us to determine
distinct patterns of phosphorylation induced by different agonists.
Our assay utilizes the unique ability of G protein-coupled receptor
kinases (GRKs) to detect only active conformations of GPCRs.
Different phosphorylation patterns may hence reflect distinct
receptor conformations.
Materials and Methods
Reagents and Antibodies
Pasireotide and octreotide were provided by Dr. Herbert
Schmid (Novartis, Basel, Switzerland). Somatoprim was provided
by Dr. Ursula Hoffmann (DeveloGen, Go ¨ttingen, Germany).
Somatostatin (SS-14) was obtained from Bachem (Weil am Rhein,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39458Germany). The phosphorylation-independent rabbit monoclonal
anti-sst2 {UMB-1}, anti-sst3 {UMB-5} or anti-sst5 {UMB-4}
antibodies were obtained from Epitomics (Burlingame, CA). The
rabbit polyclonal phosphosite-specific sst2 antibodies anti-pT353/
pT354 {0521}, anti-pT356/pT359 {0522}, and anti-pS341/
pS343 {3155} were generated and extensively characterized
previously [9,10].
Generation of Mutant Somatostatin Receptors
A chimera of the human sst5 receptor with the carboxyl-
terminal tail of the human sst2 receptor (hsst5-sst2CT) was
generated by DNA synthesis by imaGenes (Berlin, Germany). A
chimera of the rat sst3 receptor with the carboxyl-terminal tail of
the rat sst2 receptor (rsst3-sst2ACT) was generated by exchange of
the entire carboxyl-terminal tail using the FLS Motive present in
the DNA sequence of both receptors in the seventh trans-
membrane domain. The fragments were cloned into pcDNA3.1(+)
using HindIII and XbaI cloning sites.
Cell Culture and Transfection
Human embryonic kidney HEK293 cells were obtained from
the German Resource Centre for Biological Material (DSMZ,
Braunschweig, Germany). HEK293 cells were grown in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal calf
serum in a humidified atmosphere containing 10% CO2. Cells
were transfected with plasmids encoding for wild-type or mutant
somatostatin receptors using jetPEI
TM according to the instruc-
tions of the manufacturer (Invitrogen, Carlsbad, CA). Stable
transfectants were selected in the presence of 400 mg/ml G418.
HEK293 cells stably expressing somatostatin receptors were
characterized using radioligand-binding assays, Western blot
analysis, and immunocytochemistry as described previously. The
level of somatostatin receptor expression was ,900 fmol/mg
membrane protein. All chimeras and mutants tested were present
at the cell surface and expressed similar amounts of receptor
protein. The IC50 values of SS-14, octreotide and pasireotide for
ligand binding affinities are given in Table S1.
Immunocytochemistry
Cells were grown on poly-L-lysine-coated coverslips overnight.
After the appropriate treatment with SS-14, octreotide, pasireotide
or somatoprim, cells were fixed with 4% paraformaldehyde and
0.2% picric acid in phosphate buffer (pH 6.9) for 30 min at room
temperature and washed several times. Specimens were permea-
bilized and then incubated with anti-sst2 {UMB-1}, anti-sst3
{UMB-5} or anti-sst5 {UMB-4} antibodies followed by Alexa488-
conjugated secondary antibodies (Amersham, Braunschweig,
Germany). Specimens were mounted and examined using a Zeiss
LSM510 META laser scanning confocal microscope [11].
Western Blot Analysis
Stably transfected HEK293 cells were plated onto poly-L-lysine-
coated 60-mm dishes and grown to 80% confluence. After the
appropriate treatment with SS-14, octreotide, pasireotide or
somatoprim, cells were lysed in detergent buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM NaF,
Figure 1. Agonist-selective internalization of human somatostatin receptors. HEK293 cells stably expressing sst2, sst3 or sst5 receptors were
treated with either 1 mM SS-14, octreotide, pasireotide or somatoprim for 0 or 30 min. Cells were fixed, immunoflurescently stained with anti-sst2
{UMB-1}, anti-sst3 {UMB-5} or anti-sst5 {UMB-4} antibodies, and examined by confocal microscopy. Shown are representative images from one of three
independent experiments performed in duplicate. Scale bar,2 0mm.
doi:10.1371/journal.pone.0039458.g001
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deoxycholate, 0.1% SDS, 0.2 mM phenylmethylsulfonyl fluoride,
10 mg/ml leupeptin, 1 mg/ml pepstatin A, 1 mg/ml aprotinin, and
10 mg/ml bacitracin). Glycosylated proteins were partially en-
riched using wheat germ lectin-agarose beads as described
[12,13,14]. Proteins were eluted from the beads using SDS-sample
buffer for 20 min at 60uC and then resolved on 10% SDS-
polyacrylamide gels. After electroblotting, membranes were in-
cubated with the phosphosite-specific antibodies anti-pS341/
pS343 {3157}, anti-pT353/pT354 {0521} or anti-pT356/
pT359 {0522} at a concentration of 0.1 mg/ml followed by
detection using enhanced chemiluminescence (Amersham). Blots
Figure 2. Agonist-selective phosphorylation of the human sst2 receptor. (Top) Schematic representation of the human sst2 receptor
indicating the phosphate acceptor sites S341/343, T353/354 and T356/359 within its carboxyl-terminal tail. (Bottom) HEK293 cells stably expressing
the sst2 receptor were either not exposed or exposed for 5 min to SS-14, octreotide, pasireotide or somatoprim in concentrations ranging from 10
212
to 10
25 M. The levels of phosphorylated sst2 receptors were then determined using the phosphosite-specific antibodies anti-pS341/pS343 {3157},
anti-pT353/pT354 {0521} and anti-pT356/pT359 {0522}. Western blots shown are representative of three to five independent experiments for each
condition. The positions of the molecular mass markers are indicated on the left (in kDa).
doi:10.1371/journal.pone.0039458.g002
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to confirm equal loading of the gels.
Radioligand Binding Assay
Competition binding assays were performed on membrane
preparations from stable transfected cells as described above.
Cells were harvested into PBS and stored at –80uC. After
thawing, cells were centrifuged at 20,0006g for 10 min at 4uC
and then homogenized in lysis buffer (50 mM Tris-HCl, 3 mM
EGTA, 5 mM EDTA, pH 7.4). Cell membranes were pelleted
by centrifugation at 50,0006g for 15 min at 4uC, washed twice
with washing buffer (50 mM Tris-HCl, ph 7.4), and resuspended
in binding buffer (10 mM HEPES, 5 mM MgCl2,5 mg/ml
bacitracin, pH 7.5). For competition binding assay, aliquots of
the membrane preparations containing 30 mg of protein were
incubated with 0.05 nM [
125J-Tyr11]-SS-14 (specific activity:
74 TBq/mmol, PerkinElmer, USA) in the present or absence of
either SS-14, octreotide, pasireotide or somatoprim in concen-
trations ranging from 10
212 to 10
26 M. The experiment for each
concentration was performed in triplicate. Assays were performed
Figure 3. Agonist-selective phosphorylation of the human sst5 and sst5-sst2CT chimera. (A,Top panel) Schematic representation of the
sst5-sst2CT receptor indicating the phosphate acceptor sites S341/343, T353/354 and T356/359 within the carboxyl-terminal tail. (A, Bottom) HEK293
cells stably expressing the sst5-sst2ACT receptor were either not exposed or exposed for 5 min to SS-14, octreotide, pasireotide or somatoprim in
concentrations ranging from 10
212 to 10
25 M. The levels of phosphorylated sst5-sst2ACT receptors were then determined using the phosphosite-
specific antibodies anti-pS341/pS343 {3157}, anti-pT353/pT354 {0521} and anti-pT356/pT359 {0522}. (B,Top panel) Schematic representation of the
human sst5 receptor indicating the phosphate acceptor site T333 within its carboxyl-terminal tail. (B, Bottom) HEK293 cells stably expressing the
human sst5 receptors were either not exposed or exposed for 5 min to SS-14, octreotide, pasireotide or somatoprim in concentrations ranging from
10
212 to 10
25 M. The levels of phosphorylated sst5 receptors were then determined using the phosphosite-specific antibodies anti-pT333 {3567}.
Western blots shown are representative of three to five independent experiments for each condition. The positions of the molecular mass markers
are indicated on the left (in kDa).
doi:10.1371/journal.pone.0039458.g003
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45 min at room temperature. Specific binding was calculated by
subtracting non-specific binding – defined as that seen in the
presence of 1 mM SS-14, octreotide, pasireotide or somatoprim –
from total binding obtained with radioligand alone. The
incubation was terminated by addition of ice-cold buffer and
rapid vacuum filtration through glass fiber filters presoaked in
0.3% polyethyleneimine using an Inotech cell harvester (Dittikon,
Switzerland). Filters were rinsed twice with washing buffer and
air-dried. Bound radioactivity was determined using a c-counter
(COBRAII, Packard, USA). Data from ligand binding and IC50
were analyzed by curve fitting using GraphPad Prism 4.0
software [15].
GTPcS Binding Assays
Cells were harvested and lysed as described above except that
a lysis buffer containing 50 mM Tris, 10 mM EDTA and 1 mM
EGTA (pH 7.4) was used. The resulting pellet was resuspended
in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2,
pH 7.4). Aliquots containing 30 mg of protein were incubated
with 3 mM GDP and 0.05 nM [
35S]GTPcS (Specific activity –
43.3 TBq/mmol, PerkinElmer USA) in the presence or absence
of either SS-14, octreotide, pasireotide or somatoprim in
concentrations ranging from 10
212 to 10
26 M. Assays were
carried out in a final volume of 1 ml for 30 min at 30uC under
continuous agitation. Nonspecific binding was determined in the
presence of 10 mM unlabeled GTPcS. The incubation was
terminated by the addtion of ice-cold buffer and rapid vacuum
filtration through glass fiber filters as described above. Filters
were rinsed twice with washing buffer (50 mM Tris-HCl, pH 7.4)
and dried. A scintillation mixture was added, and radioactivity
was determined unsing a b-counter (1600 TR, Packard, USA)
[15].
Results
We have recently shown that pasireotide exhibits partial
agonistic properties at the sst2 receptor. While binding with high
affinity it triggers only a partial internalization of the human sst2
receptor. To test the possibility that this behavior would be
a general property of all multireceptor somatostatin analogs, we
evaluated the internalization profile of somatoprim in comparison
to pasireotide and octreotide. First, we examined human sst2, sst3
and sst5 receptors expressed in HEK293 cells by confocal
microscopy revealing that in the absence of agonist all three
somatostatin receptor subtypes were almost exclusively confined to
the plasma membrane (Figure 1, left panel). As shown in Figure 1
(upper panel), octreotide and somatoprim were able to stimulate
a robust endocytosis of human sst2 receptors similar to that seen
after SS-14 exposure. In contrast, a saturating concentration of
pasireotide induced only a very limited internalization of sst2
receptors. Conversely, examination of sst3-expressing cells re-
vealed that pasireotide promoted a more pronounced receptor
sequestration than octreotide, whereas somatoprim failed to
stimulate any detectable sst3 internalization (Figure 1, middle panel).
When sst5-expressing cells were exposed to SS-14, octreotide,
pasireotide or somatoprim only the endogenous ligand SS-14 was
able to stimulate a clearly detectable receptor endocytosis (Figure 1,
lower panel).
Recently, we have generated a set of three phosphosite-specific
antibodies, which allowed us to detect selectively the S341/S343-,
the T353/T354- and the T356/T359-phosphorylated forms of the
sst2 receptor [16,17,18,19]. When HEK293 cells stably expressing
the human sst2 receptor were exposed for 5 min to SS-14,
octreotide, pasireotide or somatoprim in concentrations ranging
from 10
212 to 10
25 M, SS-14, octreotide and somatoprim were
able to promote a robust dose-dependent phosphorylation of all
three sites (Figure 2). In contrast, pasireotide stimulated only at
saturating concentration a detectable phosphorylation of S341/
S343 and T356/T359 but not of T353/T354. Considering the
high binding affinity of pasireotide this result was unexpected and
indicates that, in contrast to octreotide and somatoprim,
pasireotide is a partial agonist at the human sst2 receptor. It also
shows that the sst2 receptor can exist in distinct active conforma-
tions, which favor different patterns of GRK-mediated phosphor-
ylation. Thus, considerable differences may exist between the
binding and efficacy profiles of pan-somatostatin analogs. It would
therefore be desirable to know the patterns of phosphorylation
induced by multireceptor ligands at the level of individual
somatostatin receptors. However, at present phosphosite-specific
antibodies are only available for the sst2 receptor.
We therefore elucidated whether the carboxyl-terminal tail of
the sst2 receptor can be used as probe to sense the activation of
other somatostatin receptors. Consequently, we transplanted the
carboxyl-terminal phosphorylation motif of the sst2 receptor to
other clinically-relevant somatostatin receptors and assessed their
patterns of activation using our set of three phosphosite-specific
antibodies. Examination of cells expressing a sst5-sst2CT chimeric
receptor revealed that SS-14 stimulated the most pronounced
phosphorylation of all three sites (Figure 3 A). Pasireotide and
somatoprim also promoted a robust phosphorylation of S341/
S343 and T356/T359 (Figure 3 A). In contrast, octreotide induced
only at saturating concentration a detectable phosphorylation of
S341/S343 and T356/T359 (Figure 3 A). Interestingly, similar
results were obtained at the wild-type sst5 receptor using a recently
generated phosphosite-specific antibody to T333 validating our
approach to study receptor activation (Figure 3 B). Analysis of
ligand binding properties of the sst5-sst2CT chimera indicated that
the transfer of the sst2 carboxyl-terminal tail to sst5 did not
substantially affect the affinities for SS-14, octreotide, pasireotide
or somatoprim (Table 1).
We then examined the capacity of these compounds to stimulate
GTPcS binding in membrane preparations from the same cells
(Figure 4). Unlike that seen in sst2 receptor phosphorylation assays,
pasireotide was able stimulate GTPcS binding to a similar degree
as octreotide or somatoprim suggesting that pasireotide is a G
protein-biased ligand. In contrast, octreotide stimulated GTPcS
binding in both sst5- and sst5-sst2CT-expressing cells to a much
lesser extend than pasireotide or somatoprim suggesting it is
indeed a weak partial agonist at the sst5 receptor. Again similar
Table 1. Ligand binding properties of sst5-sst2CT receptors.
Ligand Ligand binding affinity IC50 (nM)
human sst2 human sst5 human sst5-2CT
SS-14 5.761.1 15.562.6 30.365.0
Octreotide 1.460.3 28.964.2 38.8611.7
Pasireotide 21.365.7 3.661.5 10.865.3
Somatoprim 4.760.6 5.662.2 5.461.6
Ligand binding assays were carried out as described under ‘‘Materials and
Methods’’. The half-maximal inhibitory concentrations (IC50) were analyzed by
nonlinear regression curve fitting using the computer program GraphPad Prism.
Data are presented as the mean of three independent experiments performed
in triplicate.
doi:10.1371/journal.pone.0039458.t001
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35S-GTPcS binding. Stimulation of [
35S]GTPcS binding by SS-14, Octreotide, Pasireotide and Somatoprim in the
concentration range of 10
212 to 10
26 M. Membranes wer prepared from HEK293 cells stably expressing either the human sst2, sst5 and sst5-sst2ACT or
the rat sst3-sst2ACT receptor. Values represent means of triplicate determinations. SE values were smaller than 15%. Three replicate experiments gave
similar results.
doi:10.1371/journal.pone.0039458.g004
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receptor.
To elucidate whether our approach can be used to directly
assess the activation of a wide variety of G protein-coupled
receptors, we next examined a sst3-sst2CT chimera. Examination
of HEK293 cells stably expressing sst3-sst2CT receptors revealed
that only pasireotide but not octreotide was able to promote
a robust phosphorylation of S341/S343 and T356/T359
(Figure 5). In contrast, somatoprim failed to induce any detectable
phosphorylation. Pasireotide is less potent than octreotide in
inducing internalization of the sst2 receptor but more potent than
octreotide in inducing internalization of the sst3 receptor. Thus,
Figure 5. Agonist-selective phosphorylation of the sst3-sst2CT chimera. (Top) Schematic representation of the rat sst3-sst2CT chimera
indicating the phosphate acceptor sites S341/343, T353/354 and T356/359 within the carboxyl-terminal tail. (Bottom) HEK293 cells stably expressing
the rat sst3-sst2ACT receptor were either not exposed or exposed to concentrations of 10
212 to 10
25 M SS-14, octreotide, pasireotide or somatoprim
for 5 min. The levels of phosphorylated rsst3-sst2ACT receptors were then determined using anti-pS341/pS343 {3157}, anti-pT353/pT354 {0521} or
anti-pT356/pT359 {0522}. Western blots shown are representative of three to five independent experiments for each condition. The positions of the
molecular mass markers are indicated on the left (in kDa).
doi:10.1371/journal.pone.0039458.g005
Rapid Detection of GPCR Activation
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39458the patterns of phosphorylation of the rsst3-sst2CT chimera
correlates very well with pattern internalization of the wild-type
sst3 receptor (Figure 1). Nevertheless, it should be noted that these
results were obtained with rat sst3-sst2CT receptor construct.
Given the recently observed species differences for the sst2
receptor, these results need to be reproduced with the human
sst3 receptor.
Discussion
The development of new drugs targeting GPCRs is primarily
focused on the discovery of compounds with nanomolar and
subnanomolar binding affinities. Then indirect methods mostly
assessing G protein signaling are being used to determine whether
a new compound is a full or partial agonist. Accumulating
evidence suggests that more than one active conformation exists
for many GPCRs and that many compounds selectively stimulate
specific signaling pathways [20]. Thus, there is clearly a need for
methods providing more direct information on receptor activation.
However, structural information is only available for a few
activated receptors, and none of these has been crystallized in
more than one active conformation yet [21,22]. Determination of
receptor activation using biophysical methods requires insertion of
bulky fluorescent proteins into the receptor which may itself affect
receptor activation [23].
In the present study, we have used the phosphorylation motif of
the sst2 receptor to probe GPCR activation. This approach was
possible due to our recent success in generating a set of three
phosphosite-specific antibodies for the sst2 receptor which allowed
us to determine distinct patterns of phosphorylation induced by
different agonists. Given the unique ability of GRKs to detect only
active GPCRs these distinct conformations may reflect different
receptor conformations. However, phosphosite-specific antibodies
are notoriously difficult to generate and are only available for a few
receptors. We therefore elucidated whether the carboxyl-terminal
tail of the sst2 receptor can be used as probe to sense the activation
of other somatostatin receptors. Perhaps the most convincing
evidence that this might be a valid and useful approach comes
from a sst5-sst2CT chimera. In fact, the results obtained with the
sst5-sst2CT chimeric receptor and the wild-type sst5 receptor were
very similar. We have also confirmed that insertion of the sst2
phosphorylation motif into other somatostatin receptors did not
dramatically change their binding properties with regard to the
compounds tested. In addition, construction of a sst3-sst2CT
chimera was also successful indicating that this approach could be
used to examine the activation of a wide variety of GPCRs. Our
assay can be adapted to a quantitative ELISA method and thus be
applied to screening of large numbers of ligands [24]. However,
for other receptors it cannot be completely ruled out that
transplantation of the sst2CT may alter receptor function.
Therefore, a functional analysis of such chimeric receptors needs
to be performed in each case.
Our study also yielded valuable and previously unappreciated
information about the pan-somatostatin analogs currently under
clinical and preclinical examination. Pasireotide exhibited potent
agonistic activity at the sst5 receptor but only weak partial
agonistic properties at the sst2 receptor. Consequently, pasireotide
should be classified as sst5-preferring ligand. Octreotide is a full
agonist at the sst2 receptor but exhibited virtually no agonistic
activity at the sst5 receptor. Consequently, octreotide should be
classified as sst2-preferring ligand. In contrast, somatoprim is
unique in that it was a potent agonist at both sst2 and sst5
receptors. In fact, this may provide the molecular basis for the
recent observation that somatoprim can inhibit GH release in
cases, which did not respond to octreotide [25].
In conclusion, we describe the use of a phosphorylation probe
for direct assessment of GPCR activation and demonstrate its
utility in the pharmacological characterization of novel pan-
somatostatin analogs.
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independent experiments performed in triplicate.
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